X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (40) 40
index medicus (39) 39
oncology (36) 36
mutation (23) 23
article (22) 22
lung neoplasms - genetics (22) 22
cell line, tumor (20) 20
lung neoplasms - drug therapy (19) 19
female (18) 18
adult (15) 15
gefitinib (15) 15
middle aged (15) 15
protein kinase inhibitors - pharmacology (15) 15
cancer (14) 14
carcinoma, non-small-cell lung - genetics (14) 14
male (14) 14
animals (13) 13
mice (13) 13
antineoplastic agents - pharmacology (12) 12
aged (11) 11
cell lung-cancer (11) 11
drug resistance (11) 11
lung cancer (11) 11
lung neoplasms - pathology (11) 11
receptor, epidermal growth factor - genetics (11) 11
research (11) 11
carcinoma, non-small-cell lung - drug therapy (10) 10
cell biology (10) 10
drug resistance, neoplasm - genetics (10) 10
erlotinib (10) 10
acquired-resistance (9) 9
egfr (9) 9
growth-factor receptor (9) 9
receptor, epidermal growth factor - antagonists & inhibitors (9) 9
respiratory tract diseases (9) 9
genetic aspects (8) 8
mutations (8) 8
protein kinase inhibitors - therapeutic use (8) 8
sensitivity (8) 8
therapy (8) 8
activation (7) 7
aged, 80 and over (7) 7
carcinoma, non-small-cell lung - pathology (7) 7
tumors (7) 7
biochemistry & molecular biology (6) 6
drug resistance, neoplasm (6) 6
expression (6) 6
growth-factor-receptor (6) 6
hemic and lymphatic diseases (6) 6
lung neoplasms - metabolism (6) 6
neoplasms (6) 6
prognosis (6) 6
proteins (6) 6
quinazolines - pharmacology (6) 6
resistance (6) 6
signal transduction (6) 6
xenograft model antitumor assays (6) 6
1st-line treatment (5) 5
adenocarcinoma - genetics (5) 5
amplification (5) 5
epidermal growth factor receptor (5) 5
genes (5) 5
health aspects (5) 5
inhibitor (5) 5
lung cancer, non-small cell (5) 5
multiple myeloma (5) 5
neoplasm staging (5) 5
oncogene proteins, fusion - genetics (5) 5
phosphorylation (5) 5
receptor, epidermal growth factor - metabolism (5) 5
signal transduction - drug effects (5) 5
treatment outcome (5) 5
tyrosine kinase (5) 5
adenocarcinoma (4) 4
adenocarcinoma - drug therapy (4) 4
adenocarcinoma of lung (4) 4
amino acid substitution (4) 4
antineoplastic agents - therapeutic use (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
biomarkers, tumor - genetics (4) 4
breast cancer (4) 4
breast neoplasms - genetics (4) 4
care and treatment (4) 4
cell proliferation - drug effects (4) 4
chemotherapy (4) 4
disease-free survival (4) 4
drug therapy (4) 4
drug-resistance (4) 4
gene (4) 4
gene amplification (4) 4
gene fusions (4) 4
gene mutations (4) 4
hematology (4) 4
identification (4) 4
imatinib (4) 4
inhibition (4) 4
inhibitors (4) 4
kinase inhibitor (4) 4
kinases (4) 4
models, molecular (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Nature, ISSN 0028-0836, 12/2009, Volume 462, Issue 7276, pp. 1070 - 1074
Journal Article
Nature Medicine, ISSN 1078-8956, 03/2012, Volume 18, Issue 3, pp. 382 - 384
Journal Article
Nature Medicine, ISSN 1078-8956, 11/2013, Volume 19, Issue 11, pp. 1469 - 1472
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 17, pp. 2173 - 2181
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2017, Volume 23, Issue 1, pp. 204 - 213
Journal Article
Proceedings of the National Academy of Sciences, ISSN 0027-8424, 11/2014, Volume 111, Issue 45, pp. E4869 - E4877
The human FGF receptors (FGFRs) play critical roles in various human cancers, and several FGFR inhibitors are currently under clinical investigation.... 
Structure-based drug design | Drug discovery | Cancer drug resistance | Kinase inhibitor | structure-based drug design | WILD-TYPE | MULTIDISCIPLINARY SCIENCES | BCR-ABL | GROWTH-FACTOR RECEPTORS | DRUG-RESISTANCE | kinase inhibitor | LUNG-CANCER | GENE FUSIONS | cancer drug resistance | SELECTIVE INHIBITOR | drug discovery | THERAPEUTIC TARGET | FACTOR RECEPTOR 4 | REGULATES PROLIFERATION | Receptor, Fibroblast Growth Factor, Type 4 - chemistry | Receptor, Epidermal Growth Factor - genetics | Receptor, Fibroblast Growth Factor, Type 4 - metabolism | Receptor, Fibroblast Growth Factor, Type 2 - chemistry | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Humans | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Crystallography, X-Ray | Structure-Activity Relationship | Mutation, Missense | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Protein Kinase Inhibitors - chemistry | Receptor, Epidermal Growth Factor - metabolism | Neoplasms - genetics | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Receptor, Fibroblast Growth Factor, Type 4 - genetics | Binding Sites | Neoplasms - enzymology | Antineoplastic Agents - chemistry | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Receptor, Epidermal Growth Factor - chemistry | Neoplasms - drug therapy | Drug Resistance, Neoplasm - genetics | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Kinase Inhibitors - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - chemistry | Neoplasms - pathology | Receptor, Fibroblast Growth Factor, Type 4 - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Amino Acid Substitution | Drug Resistance, Neoplasm - drug effects | Biological Sciences | PNAS Plus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 10/2013, Volume 110, Issue 42, pp. 17041 - 17046
Breast Cancer Type 1 Susceptibility Protein (BRCA1)-deficient cells have compromised DNA repair and are sensitive to poly(ADP-ribose) polymerase (PARP)... 
Proteins | BRCA proteins | Platinum | DNA | Cell lines | Small interfering RNA | Cellular immunity | Breast cancer | Genetic mutation | Tumors | Cancer therapy | Homologous recombination | cancer therapy | POLY(ADP-RIBOSE) POLYMERASE | CELLS | REPAIR | homologous recombination | TUMOR SUPPRESSION | 53BP1 | MULTIDISCIPLINARY SCIENCES | BREAST CANCERS | OVARIAN CARCINOMAS | MUTATIONS | CHEMOTHERAPY | Humans | Ovarian Neoplasms - pathology | Ovarian Neoplasms - genetics | BRCA1 Protein - metabolism | Tumor Suppressor Proteins - genetics | Female | Antineoplastic Agents - pharmacology | HSP90 Heat-Shock Proteins - genetics | Ovarian Neoplasms - metabolism | Nuclear Proteins - genetics | Fanconi Anemia Complementation Group N Protein | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Protein Structure, Tertiary | Rad51 Recombinase - metabolism | Tumor Suppressor Proteins - metabolism | Rad51 Recombinase - genetics | Nuclear Proteins - metabolism | Cisplatin - pharmacology | Lactams, Macrocyclic - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors | Benzoquinones - pharmacology | BRCA1 Protein - genetics | Drug Resistance, Neoplasm - genetics | Poly(ADP-ribose) Polymerases - metabolism | BRCA2 Protein - metabolism | Poly(ADP-ribose) Polymerases - genetics | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Cell Line, Tumor | HSP90 Heat-Shock Proteins - metabolism | Mutation | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Gene mutations | Physiological aspects | Genetic aspects | Research | Binding proteins | Health aspects | Biological Sciences
Journal Article
Cancer Research, ISSN 0008-5472, 05/2017, Volume 77, Issue 10, pp. 2712 - 2721
Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non-small cell lung cancer (NSCLC) patients with tumors harboring these... 
CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | ONCOLOGY | ADENOCARCINOMAS | RESISTANCE | OPEN-LABEL | MUTATIONS | TUMORS | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Exons | Humans | Middle Aged | Molecular Conformation | Receptor, ErbB-2 - chemistry | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - chemistry | Codon | Adult | Female | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Disease Models, Animal | Lung Neoplasms - genetics | Gene Expression | Models, Molecular | Treatment Outcome | Antineoplastic Agents - chemistry | Receptor, Epidermal Growth Factor - chemistry | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Protein Binding | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Mutagenesis, Insertional | Protein Kinase Inhibitors - pharmacology | Lung Neoplasms - diagnosis | Amino Acid Substitution | Epidermal growth factor receptors | Lung cancer | Insertion | Non-small cell lung carcinoma | Drug resistance | Patients | ErbB-2 protein | Mutants | Sensitivity | Covalence | Inhibitors | Mutation | Tumors | Cancer | human epidermal growth factor receptor 2 | drug resistance | tyrosine kinase inhibitor | exon 20 | Epidermal growth factor receptor
Journal Article
Journal Article
Leukemia, ISSN 0887-6924, 01/2019, Volume 33, Issue 1, pp. 266 - 270
Journal Article
Cell, ISSN 0092-8674, 09/2012, Volume 150, Issue 6, pp. 1107 - 1120
Journal Article